About BIOS

The Johns Hopkins Brain Injury Outcomes (BIOS) Division is a clinical trial coordinating center (data management center, imaging reading center, and enrollment center) within the Johns Hopkins School of Medicine Department of Neurology. Its focus is to provide multicenter management to clinical trials evaluating therapeutic, preventive and diagnostic interventions. Led by Dr. Daniel F. Hanley, BIOS has unique expertise in the coordination and management of trials investigating rare neurologic disorders, acute neurologic ICU conditions, rehabilitation, and functional outcomes. Since the 1990s, BIOS has coordinated international, federally funded and industry-sponsored trials across a wide range of conditions for investigators within the JHU departments of Neurology, Neurosurgery, Anesthesiology/Critical Care Medicine, Hematology and Neuroradiology, as well as for investigators at other academic centers around the U.S.

 Read More

Johns Hopkins-Tufts TIC

BIOS and the Johns Hopkins Institute for Clinical and Translational Research (ICTR) have been awarded a seven-year, $25 million grant from the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) to form, along with Tufts University School of Medicine, one of three Trial Innovation Centers (TICs).

The goal of the centers is to promote innovations in the efficiency and quality of NIH-funded trials. The centers are part of the NCATS Trial Innovation Network and will work with the national Clinical and Translational Science Awards Program, which funds a consortium of 64 medical research institutions in 31 states and the District of Columbia. The centers will help the institutions form a long-standing infrastructure for multicenter studies to be funded by NIH and other funding agencies.

 Read More


Neurocritical Care Society Podcast on MISTIE III

For the November 2019 episode of the Neurocritical Care Society Podcast Series, Dr. Fawaz Al-Mufti was joined by Drs. Daniel Hanley and Issam Awad to discuss the results of the MISTIE III trial.  Read More

Dan Hanley Named Deputy Director of Johns Hopkins ICTR

Dr. Daniel Hanley, director of the BIOS Division, has been named the Deputy Director for Support and Innovation in Multicenter Trials at the Johns Hopkins Institute for Clinical and Translational Research.  Read More

MISTIE III: ‘A Big Step in the Right Direction’

The Journal of NeuroInterventional Surgery reports that though the MISTIE III trial did not reach its primary endpoint of improved functional outcome at one year, it did generate a wealth of high-quality data that provide invaluable insight into this devastating disease.  Read More

Recent Publications

Surgical performance determines functional outcome benefit in the MISTIE procedure.
Awad IA, Polster SP, Carrión-Penagos J, et al. Neurosurgery. 2019;84(6):1157-68.

Read Article

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.
Hanley DF, Thompson RE, Rosenblum M, et al. Lancet. 2019;393(10175):1021-32.

Read Article

Enhancing the informed consent process using shared decision making and consent refusal data from the CLEAR III trial.
Porter AL, Ebot J, Lane K, et al. Neurocritical Care. 2019 September 30.

Read Article

Intensive blood pressure reduction and perihematomal edema expansion in deep intracerebral hemorrhage.
Leasure AC, Qureshi AI, Murthy SB, et al. Stroke. 2019;50(8):2016-22.

Read Article

Joomla3 Appliance - Powered by TurnKey Linux